TLR4 and breast cancer: The detection of TLR4+/pSTAT3+ CTCs prevailed in patients with triple-negative BC over ER+ and/or PR+/HER2− and HER2+ BC settings (in 25% vs. 9.4% vs. 0% of patients, respectively; p = 0.031).